Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company ...

Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused ...

South Beloit High School is notifying families after cases of a highly contagious skin infection were detected in several ...

Lakewood-Amedex Biotherapeutics Inc., a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, ...

Armata Pharmaceuticals ( ($ARMP) ) has issued an update. On October 22, 2025, Armata Pharmaceuticals announced positive results from its Phase 2a ...

ATLANTA -- For patients with cardiovascular implantable electronic device (CIED)-associated infections, a shorter course of ...

Armata Pharmaceuticals (ARMP) stock soars 300% after the company announces promising Phase 2 trial results for its AP-SA02 antibacterial agent. Read more here.

The company’s bacteriophage therapy AP-SA02 achieved an 88% response rate in a Phase 2a trial for Staphylococcus aureus ...

Armata Pharmaceuticals said its experimental treatment for a serious bloodstream infection showed positive results in a recent mid-stage trial.

A 3-year-old girl who is in the maintenance phase of chemotherapy for leukemia is seen for a moderately painful rash on her ...

The republic is reviewing its action plan to better control the emergence and spread of future drug-resistant superbugs.

Investing.com -- Armata Pharmaceuticals (NYSE American:ARMP) stock surged 95% following the announcement of positive Phase 2a clinical trial results for its bacteriophage treatment targeting ...